EW

SEC source: 0001225208-18-011520 · doc4.xml · nonDerivative · entry 2

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,465

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.

F2 · price: This transaction was executed in multiple trades at prices ranging from $146.16 to $146.49. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-18-011520 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.

SEC source: 0001225208-18-010776 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,800

Underlying: Common Stock · 6,300 shares

Expires 2019-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017.

SEC source: 0001225208-18-010776 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,155.9644

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017.

SEC source: 0001225208-18-010776 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · CVP, THV Replacement

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,455.9644

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017.

SEC source: 0001225208-18-010711 · doc4.xml · derivative · entry 5

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,100

Underlying: Common Stock · 5,500 shares

Expires 2019-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018.

SEC source: 0001225208-18-010711 · doc4.xml · nonDerivative · entry 3

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 50,785

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018.

SEC source: 0001225208-18-010711 · doc4.xml · nonDerivative · entry 2

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,012.2823

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018.

SEC source: 0001225208-18-010711 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,512.2823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018.

SEC source: 0001225208-18-010292 · doc4.xml · derivative · entry 5

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,036

Underlying: Common Stock · 25,000 shares

Expires 2021-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.

SEC source: 0001225208-18-010292 · doc4.xml · nonDerivative · entry 3

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,265

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.

F3 · price: This transaction was executed in multiple trades at prices ranging from $140.40 to $141.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-18-010292 · doc4.xml · nonDerivative · entry 2

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,775

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.

F2 · price: This transaction was executed in multiple trades at prices ranging from $141.43 to $141.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-18-010292 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.

SEC source: 0001225208-18-010236 · doc4.xml · derivative · entry 3

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,800

Underlying: Common Stock · 3,800 shares

Expires 2019-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018.

SEC source: 0001225208-18-010236 · doc4.xml · nonDerivative · entry 2

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,587.6173

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018.

SEC source: 0001225208-18-010236 · doc4.xml · nonDerivative · entry 1

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,387.6173

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018.

SEC source: 0001225208-18-009851 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,001.2313

SEC source: 0001225208-18-009850 · doc4.xml · nonDerivative · entry 2

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 54,785

F2 · price: This transaction was executed in multiple trades at prices ranging from $137.50 to $137.5450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-18-009850 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,012.2823

F1 · price: This transaction was executed in multiple trades at prices ranging from $137.50 to $137.5850. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-18-009759 · doc4.xml · nonDerivative · entry 3

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,134

F2 · shares: This restricted stock was granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

SEC source: 0001225208-18-009759 · doc4.xml · nonDerivative · entry 2

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,655

F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

SEC source: 0001225208-18-009758 · doc4.xml · nonDerivative · entry 4

VON SCHACK WESLEY W · CIK 0001025355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,134

F2 · shares: This restricted stock was granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

SEC source: 0001225208-18-009758 · doc4.xml · nonDerivative · entry 3

VON SCHACK WESLEY W · CIK 0001025355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,655

F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

SEC source: 0001225208-18-009757 · doc4.xml · derivative · entry 2

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,913

Underlying: Common Stock · 1,913 shares

Expires 2025-05-17

F2 · shares: These options were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

F2 · derivative.exercise_date: These options were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

SEC source: 0001225208-18-009757 · doc4.xml · nonDerivative · entry 1

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,689

F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

SEC source: 0001225208-18-009756 · doc4.xml · nonDerivative · entry 1

VALERIANI NICHOLAS J · CIK 0001263149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,672

F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

SEC source: 0001225208-18-009755 · doc4.xml · nonDerivative · entry 1

Marsh Martha H. · CIK 0001500281 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,630

F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

SEC source: 0001225208-18-009754 · doc4.xml · derivative · entry 3

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,913

Underlying: Common Stock · 1,913 shares

Expires 2025-05-17

F2 · shares: These options were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

F2 · derivative.exercise_date: These options were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

SEC source: 0001225208-18-009754 · doc4.xml · nonDerivative · entry 1

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,218

F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

SEC source: 0001225208-18-009753 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,730

F2 · shares: This restricted stock was granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

SEC source: 0001225208-18-009753 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,251

F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

SEC source: 0001225208-18-009686 · doc4.xml · derivative · entry 2

Chopra Daveen · CIK 0001740963 · CVP, Surgical HVT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,145

Underlying: Common Stock · 16,145 shares

Expires 2025-05-16

F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-18-009686 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, Surgical HVT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,209

F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

SEC source: 0001225208-18-009683 · doc4.xml · derivative · entry 3

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,650

Underlying: Common Stock · 1,650 shares

Expires 2025-05-16

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

SEC source: 0001225208-18-009683 · doc4.xml · derivative · entry 2

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Stock · 13,000 shares

Expires 2025-05-16

F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments.

SEC source: 0001225208-18-009683 · doc4.xml · nonDerivative · entry 1

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,587.6173

F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

SEC source: 0001225208-18-009684 · doc4.xml · derivative · entry 9

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,250

Underlying: Common Stock · 13,250 shares

Expires 2025-05-16

F7 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F7 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F7 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F7 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F7 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

SEC source: 0001225208-18-009684 · doc4.xml · derivative · entry 8

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,300

Underlying: Common Stock · 104,300 shares

Expires 2025-05-16

F6 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments.

SEC source: 0001225208-18-009684 · doc4.xml · derivative · entry 7

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286,900

Underlying: Common Stock · 32,900 shares

Expires 2019-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018.

SEC source: 0001225208-18-009684 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,430.82

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018.

F4 · price: This transaction was executed in multiple trades at prices ranging from $135.23 to $136.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-18-009684 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,530.82

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018.

F3 · price: This transaction was executed in multiple trades at prices ranging from $136.23 to $136.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-18-009684 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,330.82

F2 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

SEC source: 0001225208-18-009684 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,730.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018.

SEC source: 0001225208-18-009681 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,025

Underlying: Common Stock · 2,025 shares

Expires 2025-05-16

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

SEC source: 0001225208-18-009681 · doc4.xml · derivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,900

Underlying: Common Stock · 15,900 shares

Expires 2025-05-16

F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments.

SEC source: 0001225208-18-009681 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,373.0233

F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

SEC source: 0001225208-18-009682 · doc4.xml · derivative · entry 2

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,070

Underlying: Common Stock · 3,070 shares

Expires 2025-05-16

F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-18-009682 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,161.3091

F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

SEC source: 0001225208-18-009680 · doc4.xml · derivative · entry 5

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires 2025-05-16

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

SEC source: 0001225208-18-009680 · doc4.xml · derivative · entry 4

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,500

Underlying: Common Stock · 23,500 shares

Expires 2025-05-16

F3 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments.